Organogenesis (ORGO) Set to Announce Earnings on Thursday

Organogenesis (NASDAQ:ORGO) is scheduled to be issuing its quarterly earnings data after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.03) per share for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

Organogenesis Stock Up 2.1 %

Shares of NASDAQ ORGO opened at $2.44 on Wednesday. Organogenesis has a 52 week low of $1.96 and a 52 week high of $4.70. The stock’s fifty day moving average is $2.80 and its 200 day moving average is $3.09. The company has a debt-to-equity ratio of 0.22, a quick ratio of 2.44 and a current ratio of 2.80. The stock has a market capitalization of $321.98 million, a P/E ratio of 61.02 and a beta of 1.60.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald reiterated an “overweight” rating and set a $5.00 price target on shares of Organogenesis in a research report on Friday, March 1st.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.